Header Logo

Connection

Anthony Rothschild to Psychotic Disorders

Back to Details
This is a "connection" page, showing publications Anthony Rothschild has written about Psychotic Disorders.
Anthony Rothschild
Connection Strength
6.325
Psychotic Disorders
  1. Rothschild AJ. Maintenance treatment of psychotic depression: Is antipsychotic medication needed? Acta Psychiatr Scand. 2024 01; 149(1):3-5.
    View in: PubMed
    Score: 0.779
  2. Rothschild AJ. Why Is There No Food and Drug Administration-Approved Medication for Major Depression With Psychotic Features? J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):359-361.
    View in: PubMed
    Score: 0.655
  3. Rothschild AJ. Psychotic depression and suicide. Acta Psychiatr Scand. 2018 04; 137(4):364-365.
    View in: PubMed
    Score: 0.523
  4. Zalpuri I, Rothschild AJ. Does psychosis increase the risk of suicide in patients with major depression? A systematic review. J Affect Disord. 2016 07 01; 198:23-31.
    View in: PubMed
    Score: 0.454
  5. Rothschild AJ, Winer J, Flint AJ, Mulsant BH, Whyte EM, Heo M, Fratoni S, Gabriele M, Kasapinovic S, Meyers BS. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008 Aug; 69(8):1293-6.
    View in: PubMed
    Score: 0.268
  6. Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.
    View in: PubMed
    Score: 0.213
  7. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004 Aug; 24(4):365-73.
    View in: PubMed
    Score: 0.203
  8. Cintr?n Pastrana MA, Irizarry Flores JC, Rothschild AJ. Challenges in the Treatment of Psychotic Bipolar Depression. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):407-412.
    View in: PubMed
    Score: 0.201
  9. Banerjee S, Wu Y, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Oliver LD, Power JD, Rothschild AJ, Sirey JA, Voineskos AN, Whyte EM, Alexopoulos GS, Flint AJ. Trajectories of remitted psychotic depression: identification of predictors of worsening by machine learning. Psychol Med. 2024 Apr; 54(6):1142-1151.
    View in: PubMed
    Score: 0.192
  10. Bingham KS, Calarco N, Dickie EW, Alexopoulos GS, Butters MA, Meyers BS, Marino P, Neufeld NH, Rothschild AJ, Whyte EM, Mulsant BH, Flint AJ, Voineskos AN. The relationship of white matter microstructure with psychomotor disturbance and relapse in remitted psychotic depression. J Affect Disord. 2023 08 01; 334:317-324.
    View in: PubMed
    Score: 0.186
  11. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003 Apr 15; 53(8):680-90.
    View in: PubMed
    Score: 0.185
  12. Song J, Mulsant BH, Sanches M, Alexopoulos GS, Marino P, Meyers BS, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Gerretsen P. Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study. J Affect Disord. 2023 03 15; 325:29-34.
    View in: PubMed
    Score: 0.182
  13. Bingham KS, Neufeld NH, Alexopoulos GS, Marino P, Mulsant BH, Rothschild AJ, Voineskos AN, Whyte EM, Meyers BS, Flint AJ. Factor analysis of the CORE measure of psychomotor disturbance in psychotic depression: Findings from the STOP-PD II study. Psychiatry Res. 2022 08; 314:114648.
    View in: PubMed
    Score: 0.174
  14. Patel DA, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS, Mulsant BH, Voineskos AN, Marino P, Alexopoulos GS. Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. J Clin Psychopharmacol. 2021 Mar-Apr 01; 41(2):196-199.
    View in: PubMed
    Score: 0.160
  15. Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Lerch JP, Flint AJ. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020 07 01; 77(7):674-683.
    View in: PubMed
    Score: 0.153
  16. Neufeld NH, Kaczkurkin AN, Sotiras A, Mulsant BH, Dickie EW, Flint AJ, Meyers BS, Alexopoulos GS, Rothschild AJ, Whyte EM, Mah L, Nierenberg J, Hoptman MJ, Davatzikos C, Satterthwaite TD, Voineskos AN. Structural brain networks in remitted psychotic depression. Neuropsychopharmacology. 2020 06; 45(7):1223-1231.
    View in: PubMed
    Score: 0.149
  17. Bingham KS, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM, Banerjee S, Artis AS, Alexopoulos GS, Flint AJ. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018 09; 138(3):267-273.
    View in: PubMed
    Score: 0.133
  18. Victoria LW, Whyte EM, Butters MA, Meyers BS, Alexopoulos GS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2017 Jun; 25(6):672-679.
    View in: PubMed
    Score: 0.121
  19. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Hum Psychopharmacol. 2016 05; 31(3):252-5.
    View in: PubMed
    Score: 0.114
  20. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD. Clin Pharmacokinet. 2015 Nov; 54(11):1161-8.
    View in: PubMed
    Score: 0.111
  21. ?stergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Leadholm AK, Bech P, Meyers BS. Rating scales measuring the severity of psychotic depression. Acta Psychiatr Scand. 2015 Nov; 132(5):335-44.
    View in: PubMed
    Score: 0.107
  22. Gerretsen P, Flint AJ, Whyte EM, Rothschild AJ, Meyers BS, Mulsant BH. Impaired insight into delusions predicts treatment outcome during a randomized controlled trial for Psychotic Depression (STOP-PD study). J Clin Psychiatry. 2015 Apr; 76(4):427-33.
    View in: PubMed
    Score: 0.106
  23. ?stergaard SD, Pedersen CH, Uggerby P, Munk-J?rgensen P, Rothschild AJ, Larsen JI, G?tzsche C, S?ndergaard MG, Bille AG, Bolwig TG, Larsen JK, Bech P. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord. 2015 Mar 01; 173:261-8.
    View in: PubMed
    Score: 0.104
  24. Davies SJ, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Compr Psychiatry. 2014 Jul; 55(5):1069-76.
    View in: PubMed
    Score: 0.098
  25. ?stergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord. 2014 May; 160:68-73.
    View in: PubMed
    Score: 0.097
  26. Leadholm AK, Rothschild AJ, Nolen WA, Bech P, Munk-J?rgensen P, Ostergaard SD. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord. 2013 Feb 20; 145(2):214-20.
    View in: PubMed
    Score: 0.089
  27. Flint AJ, Peasley-Miklus C, Papademetriou E, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM. Effect of age on the frequency of anxiety disorders in major depression with psychotic features. Am J Geriatr Psychiatry. 2010 May; 18(5):404-12.
    View in: PubMed
    Score: 0.076
  28. Rothschild AJ, Benes F, Hebben N, Woods B, Luciana M, Bakanas E, Samson JA, Schatzberg AF. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry. 1989 Oct; 26(6):565-75.
    View in: PubMed
    Score: 0.073
  29. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009 Aug; 66(8):838-47.
    View in: PubMed
    Score: 0.072
  30. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007 Feb; 68(2):194-200.
    View in: PubMed
    Score: 0.060
  31. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006 Sep; 86(1-3):234-43.
    View in: PubMed
    Score: 0.058
  32. Ihaddadene RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial. Psychiatry Res. 2024 Dec; 342:116192.
    View in: PubMed
    Score: 0.051
  33. Kim HK, Voineskos AN, Neufeld NH, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Rothschild AJ, Whyte EM, Mulsant BH. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features. Mol Psychiatry. 2024 Aug; 29(8):2459-2466.
    View in: PubMed
    Score: 0.049
  34. Rothschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. Br J Psychiatry. 1982 Nov; 141:471-4.
    View in: PubMed
    Score: 0.045
  35. Bingham KS, Whyte EM, Meyers BS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2015 Dec; 23(12):1270-1275.
    View in: PubMed
    Score: 0.027
  36. Leadholm AK, Rothschild AJ, Nielsen J, Bech P, Ostergaard SD. Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression. J Affect Disord. 2014 Mar; 156:119-25.
    View in: PubMed
    Score: 0.024
  37. Blumberger DM, Mulsant BH, Kanellopoulos D, Whyte EM, Rothschild AJ, Flint AJ, Meyers BS. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression. J Clin Psychopharmacol. 2013 Jun; 33(3):391-7.
    View in: PubMed
    Score: 0.023
  38. Zarate CA, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000 Mar; 61(3):185-9.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.